$QUIK

QuickLogic Set to Join Russell 2000® and Russell 3000® Indexes

QuickLogic (NASDAQ: QUIK) said it will be added to the Russell 3000® and Russell 2000® indexes effective June 29, 2026, as part of the 2026 Russell US indexes reconstitution. Russell 3000 inclusion also brings automatic Russell 2000 membership. FTSE Russell said about $12.2 trillion was benchmarked to Russell US indexes as of end-June 2025.

Original reporting
Published Jun 2, 2026, 12:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 1:14 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
QuickLogic Set to Join Russell 2000® and Russell 3000® Indexes — source image
Decision brief

The 30-second read

$QUIKBullishMed
01

Why it matters

Traders may front-run expected rebalancing demand into the effective date and fade after implementation, while monitoring broader small-cap risk sentiment.

02

Market read

A scheduled Russell 2000/3000 addition is a mechanical catalyst that can influence near-term price action via passive fund flows.

03

What to watch

Actual impact depends on index-tracking fund implementation timing, share availability, and whether QUIK’s weight/market-cap rank meaningfully changes passive demand.

Relevance 8/10Novelty 8/10Timing: Effective June 29 (US market open) for Russell 2000/3000 inclusion.

Background

Russell US index reconstitutions (Russell 2000/3000) are widely used benchmarks; inclusion can drive systematic buying by index funds and ETFs.

Company-level read

Ticker impact

$QUIKBullishMedium confidence
Context

QuickLogic will be added to the Russell 3000 and Russell 2000 effective June 29, triggering index-fund rebalancing flows.

Expected impact

Mild positive bias into/around June 29; magnitude likely limited but could be noticeable given small-cap inclusion.

Evidence & confidence

Russell additions often create predictable buying pressure from benchmarked funds, but the article provides no size/flow estimates or guidance changes.

Market effects

May modestly improve sentiment toward embedded FPGA/eFPGA and radiation-hardened FPGA suppliers via passive ownership effects.

Primarily US small-cap/benchmark flow impact; limited direct international read-through.

Low global relevance; driven by US index methodology and ETF/benchmark tracking.

Counterpoint

If liquidity/float is thin, any pre-positioning could reverse quickly after effective date as rebalancing completes.

Key entities

  • QuickLogic Corporation

    Developer of embedded FPGA hard IP and radiation-hardened/antifuse FPGA solutions; subject of Russell index inclusion announcement.

  • FTSE Russell (LSEG business)

    Index provider responsible for Russell reconstitution methodology and effective-date schedule.

Related articles

$QUIKMed

QuickLogic (QUIK) Q2 2026 Earnings Call Transcript

QuickLogic (QUIK) reported Q2 2026 revenue at the low end of guidance due to contract delays. The company narrowed its full-year revenue growth outlook to 70-80% and expects non-GAAP profitability and positive cash flow in the second half of 2026. Growth is anticipated from RadPro, Storefront initiatives, and entries into automotive, robotics, and commercial satellite sectors. Management noted design activity transitioning to Intel 18A-P process node for performance improvements and reduced powe

$QUIKMed

QUICKLOGIC Corp (QUIK): Results of Operations and Financial Condition

QUICKLOGIC Corp (QUIK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 QuickLogic Reports Fiscal Second Quarter 2026 Financial Results SAN JOSE, Calif. – August 11, 2026 - QuickLogic® Corporation (NASDAQ: QUIK) (“QuickLogic” or the “Company”), a developer of embedded FPGA (eFPGA) Hard IP, Strategic Radiation Hardened and Antifuse FPGAs,

$ROIVMedAI 8/10

What Lisraya’s $35,000 Monthly Price Could Mean for Roivant (ROIV)

Roivant Sciences (ROIV) and Priovant Therapeutics launched Lisraya, a $35,000/month dermatomyositis treatment, post-FDA approval. The drug's high price and small patient population present challenges, but its immediate launch and long exclusivity may drive adoption. ROIV owns 71% of Priovant, making Lisraya's success crucial for its financial outlook.